The Next Phase of Real-World Clinical Experience with Alefacept: The AWARE-2 Registry

Lebwohl M Christophers E Langley R for the Alefacept Clinical Study Group. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol 2003;139:719–27.

Krueger GG Papp KA Stough DB . A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol 2002;47:821–33.

Sommer DM Jenisch S Suchan M . Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res 2006;298:321–8. [Epub 2006 Sep 22]

Goffe B Papp K Gratton K . An integrated analysis of thirteen trials summarizing the long-term safety of alefacept in psoriasis patients who have received up to nine courses of therapy. Clin Ther 2005;27:1912–21.

Gottlieb AB Boehncke W-H Darif M . Safety and efficacy of alefacept in elderly patients and other special populations. J Drugs Dermatol 2005;4:718–24.

Christophers E . Comorbidities in psoriasis. J Eur Acad Dermatol Venereol 2006;20 Suppl 2:52-–5.

Schmitt JM Ford DE . Role of depression in quality of life for patients with psoriasis. Dermatology 2007;215:17–27.

Mrowietz U Elder JT Barker J . The importance of disease associations and concomitant therapy for the long-term management of psoriasis. Arch Dermatol Res 2006;298:309–19. [Epub 2006 Oct 5]

Krueger GG Gottlieb AB Sterry W . A multicenter, open-label study of repeat courses of intramuscular alefacept in combination with other psoriasis therapies in patients with chronic plaque psoriasis. J Dermatolog Treat 2008;19:146–55.

Perlmutter A Cather J Franks B . Alefacept revisited: Our 3-year clinical experience in 200 patients with chronic plaque psoriasis. J Am Acad Dermatol 2008;58:116–24.

Rico MJ Krell JM Bagel J . Assessment and Tracking of Long-Term Alefacept Safety (ATLAS): analysis of data from approximately 1200 patients. Poster presented at the 21st World Congress of Dermatology; 2007 September 30–October 5, 2007, Buenos Aires, Argentina.

Landells I Searles G Bissonnette R . Efficacy outcomes in patients using alefacept in the AWARE study. J Cutan Med Surg 2009;13 Suppl 3:122-–30.

Mazzotti E Picardi A Sampogna F ; IDI Multipurpose Psoriasis Research on Vital Experiences Study Group. Sensitivity of the Dermatology Life Quality Index to clinical change in patients with psoriasis. Br J Dermatol 2003;149:318–22.